1,5-己二烯-2,3-二醇 | 224294-66-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1,5-己二烯-2,3-二醇
• 英文名称: 1,5-Hexadiene-2,3-diol
• 英文别名: hexa-1,5-diene-2,3-diol
• CAS: 224294-66-0
• 化学式: C₆H₁₀O₂
• 分子量: 114.14
• InChiKey: PSTBYXSYWMQNJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS
  申请人：Rodgers James D.

  公开号：US20090233903A1

  公开（公告）日：2009-09-17

  The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及吲哚啉和环丁烷衍生物，以及它们的组合物、使用方法和制备方法，这些JAK抑制剂在治疗JAK相关疾病中很有用，包括炎症性和自身免疫性疾病，以及癌症。
• Process for the Synthesis of Long-Chain Fatty Acids
  申请人：Fauq Abdul H.

  公开号：US20110105781A1

  公开（公告）日：2011-05-05

  This invention relates to processes for preparing long-chain fatty acids of Formula I: and salts thereof, as well as intermediates for the processes, wherein L 1 and L 2 are described herein.

  本发明涉及制备式I的长链脂肪酸及其盐的方法，以及用于该方法的中间体，其中L1和L2如本文所述。
• [EN] JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES<br/>[FR] INHIBITEURS DES JANUS KINASES POUR LE TRAITEMENT DU SYNDROME DE L'OEL SEC ET AUTRES MALADIES DE L'OEL
  申请人：INCYTE CORP

  公开号：WO2010039939A1

  公开（公告）日：2010-04-08

  Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.

  本发明提供了用于治疗干眼症和其他相关眼部疾病的方法、试剂盒和组合物，其中所述方法、试剂盒和组合物利用JAK抑制剂。
• [EN] AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS D'AZÉTIDINE ET DE CYCLOBUTANE EN TANT QU'INHIBITEURS DE JANUS KINASE (JAK)
  申请人：INCYTE CORP

  公开号：WO2009114512A1

  公开（公告）日：2009-09-17

  The method includes the steps of performing in-vitro liver, intestinal and/or expressed enzyme assays with selected ethnobotanical substances, for both humans and a variety of animal species, to produce an array of resulting chemical entities, such as metabolites, for the human and the animals. Comparisons are then made between the chemical entities from the human in-vitro studies and the animal in-vitro studies to determine the closest match. The animal with the closest match is then used for an in-vivo study. If a match is present between the animal in-vivo results and the human in-vitro results, the matched chemical entity is isolated or synthesized and then further tested to determine the suitability of the matched chemical entity as a treatment drug.

  该方法包括以下步骤：使用选择的民族植物物质进行体外肝脏、肠道和/或表达酶测定，针对人类和多种动物物种，以产生一系列化学实体，如代谢物，用于人类和动物。然后将人体体外研究和动物体外研究得到的化学实体进行比较，以确定最接近的匹配。然后选择最接近匹配的动物进行体内研究。如果动物体内结果与人体体外结果相匹配，则分离或合成匹配的化学实体，并进一步测试以确定匹配的化学实体是否适用于治疗药物。
• Eye treatments using synthetic thyroid hormone compositions
  申请人：The Regents of the University of California

  公开号：US20030175849A1

  公开（公告）日：2003-09-18

  The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydraulic conductivity, hyaluronic acid secretion, and extracellular matrix assembly are provided. Methods of treating glaucoma and treating excess intraocular pressure with synthetic thyroid hormones and compositions therefore are also provided.

  本发明涉及发现合成甲状腺激素可以用作组合物在体内降低眼压。提供了筛选合成甲状腺激素对眼压、房水压、水力导导性、透明质酸分泌和细胞外基质组装影响的方法。还提供了使用合成甲状腺激素和其组合物治疗青光眼和治疗过高眼压的方法。